LP
SRPT icon

LMR Partners’s Sarepta Therapeutics SRPT Stock Holding History

LMR Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48K Sell
138
-14,386
-99% -$272K ﹤0.01% 1474
2026
Q1 		$316K Sell
14,524
-15,476
-52% -$300K ﹤0.01% 1134
2025
Q4 		$646K Buy
30,000
+3,083
+11% +$65K ﹤0.01% 1076
2025
Q3 		$519K Buy
+26,917
New +$480K ﹤0.01% 1083
2025
Q1 		– Sell
-3,724
Closed -$453K – 1620
2024
Q4 		$453K Sell
3,724
-41,903
-92% -$5.14M ﹤0.01% 852
2024
Q3 		$5.7M Sell
45,627
-15,217
-25% -$2.1M 0.05% 333
2024
Q2 		$9.61M Buy
+60,844
New +$7.82M 0.08% 213
2024
Q1 		– Sell
-22,654
Closed -$2.78M – 1300
2023
Q4 		$2.18M Buy
+22,654
New +$2.17M 0.02% 451
2023
Q2 		– Sell
-44,479
Closed -$5.74M – 1097
2023
Q1 		$6.13M Buy
44,479
+25,389
+133% +$3.29M 0.1% 226
2022
Q4 		$2.47M Sell
19,090
-4,449
-19% -$516K 0.04% 463
2022
Q3 		$2.6M Sell
23,539
-90,121
-79% -$9.08M 0.05% 439
2022
Q2 		$8.52M Buy
113,660
+51,901
+84% +$3.82M 0.14% 168
2022
Q1 		$4.83M Buy
+61,759
New +$4.73M 0.06% 334
2021
Q3 		– Sell
-5,997
Closed -$466K – 1180
2021
Q2 		$466K Buy
+5,997
New +$455K 0.01% 693
2021
Q1 		– Sell
-51,986
Closed -$8.86M – 1050
2020
Q4 		$8.86M Buy
+51,986
New +$7.7M 0.14% 71
2019
Q3 		– Sell
-19,359
Closed -$2.94M – 507
2019
Q2 		$2.94M Sell
19,359
-7,267
-27% -$883K 0.11% 91
2019
Q1 		$3.17M Buy
+26,626
New +$3.42M 0.16% 93
2018
Q4 		– Sell
-37,216
Closed -$6.01M – 468
2018
Q3 		$6.01M Sell
37,216
-59,929
-62% -$8.19M 0.38% 68
2018
Q2 		$12.8M Buy
+97,145
New +$9.16M 0.67% 27

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LMR Partners's SRPT Position: Q2 2026 in Review

LMR Partners reduced its Sarepta Therapeutics (SRPT) stake by 99% in Q2 2026, selling an estimated $272K and leaving 138 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1474.

LMR Partners first reported a position in SRPT in Q2 2018 and has held it in 19 quarters since. The position peaked at $12.8M in Q2 2018. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • LMR Partners held 138 shares of Sarepta Therapeutics worth $2.48K as of Q2 2026.
  • LMR Partners sold 14,386 Sarepta Therapeutics shares in Q2 2026, an estimated $272K.
  • Sarepta Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1474 holding.
  • LMR Partners first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 19 quarters since.
  • LMR Partners's Sarepta Therapeutics position peaked at $12.8M in Q2 2018.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.